3.45
Schlusskurs vom Vortag:
$3.42
Offen:
$3.41
24-Stunden-Volumen:
537.75K
Relative Volume:
0.98
Marktkapitalisierung:
$154.10M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-32.74M
KGV:
-4.2073
EPS:
-0.82
Netto-Cashflow:
$-24.89M
1W Leistung:
-0.43%
1M Leistung:
-34.69%
6M Leistung:
-70.79%
1J Leistung:
-66.23%
Third Harmonic Bio Inc Stock (THRD) Company Profile
Firmenname
Third Harmonic Bio Inc
Sektor
Branche
Telefon
(209) 727-2457
Adresse
1700 MONTGOMERY STREET, SAN FRANCISCO
Vergleichen Sie THRD mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
THRD
Third Harmonic Bio Inc
|
3.45 | 154.10M | 0 | -32.74M | -24.89M | -0.82 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
479.79 | 121.85B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
698.74 | 76.83B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
624.67 | 37.96B | 1.86B | -40.29M | -1.28B | -0.85 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
246.75 | 30.69B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beone Medicines Ltd Adr
|
271.80 | 29.71B | 3.32B | -860.46M | -1.04B | -8.32 |
Third Harmonic Bio Inc Stock (THRD) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-02-12 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
2025-02-11 | Herabstufung | Raymond James | Outperform → Mkt Perform |
2024-08-09 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
2024-06-18 | Eingeleitet | Stifel | Buy |
2024-06-07 | Eingeleitet | Raymond James | Outperform |
2022-12-16 | Herabstufung | Jefferies | Buy → Hold |
2022-12-15 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
2022-10-10 | Eingeleitet | Cowen | Outperform |
2022-10-10 | Eingeleitet | Jefferies | Buy |
2022-10-10 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Third Harmonic Bio Inc Aktie (THRD) Neueste Nachrichten
Layoff Tracker: BMS’ Latest Cuts in New Jersey Will Affect 223 Employees - BioSpace
Companies Like Third Harmonic Bio (NASDAQ:THRD) Are In A Position To Invest In Growth - Yahoo Finance
Third Harmonic Bio downgraded to Market Perform from Outperform at Raymond James - MSN
Third Harmonic Bio progresses THB335 to Phase 2 trial - MSN
Third Harmonic Bio, Inc. (THRD) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Down -39.61% in 4 Weeks, Here's Why You Should You Buy the Dip in Third Harmonic Bio, Inc. (THRD) - Nasdaq
Third Harmonic stock rating cut by Raymond James - MSN
Third Harmonic Bio Initiates Strategic Review, Lays Off 50% Staff Citing Competitive Landscape - AOL
Raymond James downgrades Third Harmonic Bio on uncertainty for only asset - MSN
Morgan Stanley Downgrades Third Harmonic Bio to Equalweight From Overweight, Cuts Price Target to $5 From $20 - Marketscreener.com
Third Harmonic and Inventiva slash workforces - The Pharma Letter
Third Harmonic Bio progresses THB335 to Phase 2 trial By Investing.com - Investing.com Nigeria
Morgan Stanley cuts Third Harmonic stock rating amid uncertainty - MSN
Finance Watch: Third Harmonic, Q32 Bio Cut Jobs To Focus On Lead Assets - News & Insights
Morgan Stanley cuts Third Harmonic stock rating amid uncertainty By Investing.com - Investing.com Canada
Third Harmonic Bio, Inc.: Hold Rating Amid Strategic Uncertainty and Safety Concerns - TipRanks
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Optimistic Buy Rating for Third Harmonic Bio Amid Promising Trial Results and Safety Concerns - TipRanks
Third Harmonic Bio Inc (THRD) Stock: A Year of Stock Market Dynamics - The InvestChronicle
Stock market news: Fluence Energy -47.86%, Columbus McKinnon -40.83% among biggest losers during midday trading - Business Upturn
Third Harmonic stock rating cut by Raymond James By Investing.com - Investing.com South Africa
Merck KGaA pursuing Springworks; BridgeBio wins EU drug OK - BioPharma Dive
Third Harmonic Bio Shares Slump After 50% Workforce Cut, Strategic Review Set -February 11, 2025 at 10:34 am EST - Marketscreener.com
Stock market today: Fluence Energy -46.44%, Columbus McKinnon -42.05% among biggest losers in early trading - Business Upturn
Third Harmonic Bio, Inc. Announces Restructuring Plan - TipRanks
Third Harmonic Bio stock tumbles after clinical trial results - Investing.com
Hain Celestial Group Inc’s Mixed Bag: Down -43.22% in 6 Months, Down -22.12% in 30 Days - The InvestChronicle
Third Harmonic Bio stock tumbles after clinical trial results By Investing.com - Investing.com South Africa
Third Harmonic halves headcount to take urticaria drug into phase 2 despite side effects - Fierce Biotech
Third Harmonic Bio Announces Phase 1 Clinical Results for THB335 and Provides Corporate Strategic Update - The Manila Times
Third Harmonic Bio Announces Phase 1 Clinical Results for THB335 and Provides Corporate - The Bakersfield Californian
Third Harmonic Bio Announces Phase 1 Clinical Results for THB335 -February 11, 2025 at 07:00 am EST - Marketscreener.com
(THRD) Investment Analysis - Stock Traders Daily
Spruce Biosciences Inc (NASDAQ: SPRB) Stock Has Gained 4.05% Over The Month – Is There Room For Growth? - Marketing Sentinel
Should You Expect Akero Therapeutics Inc (NASDAQ:AKRO) To Recover From Its 70.02% Gain From Highs? - Marketing Sentinel
Five Point Holdings LLC (NYSE: FPH): Can The Stock Still Lose Despite An 54.23% YTD Gain? - Marketing Sentinel
After Falling -7.79% During The Past Week, Should You Still Buy Third Harmonic Bio Inc (NASDAQ: THRD)? - Marketing Sentinel
Analytical Overview: Orasure Technologies Inc (OSUR)’s Ratios Tell a Financial Story - The Dwinnex
Balance Sheet Insights: Chart Industries Inc (GTLS)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Ratios Reveal: Breaking Down Third Harmonic Bio Inc (THRD)’s Financial Health - The Dwinnex
Finanzdaten der Third Harmonic Bio Inc-Aktie (THRD)
Umsatz
Nettogewinn
Free Cashflow
ENV
Third Harmonic Bio Inc-Aktie (THRD) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
Conner Edward R. | Chief Medical Officer |
Nov 08 '24 |
Sale |
15.00 |
2,117 |
31,755 |
0 |
BVF PARTNERS L P/IL | See Explanation of Responses |
Oct 29 '24 |
Sale |
14.30 |
1,000,000 |
14,300,000 |
176,692 |
Conner Edward R. | Chief Medical Officer |
Oct 28 '24 |
Option Exercise |
4.20 |
2,673 |
11,227 |
2,673 |
Conner Edward R. | Chief Medical Officer |
Oct 28 '24 |
Sale |
15.00 |
2,673 |
40,095 |
0 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):